TCT-103 The Transaortic Approach for Transcatheter Aortic Valve Replacement: Initial Clinical Experience in the United States

Background The Edwards SAPIEN valve has been FDA-approved with its Retroflex delivery system for retrograde transfemoral (TF) treatment of inoperable patients with severe aortic stenosis, and is the only device clinically available for transcatheter aortic valve replacement (TAVR) in the United Stat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2012-10, Vol.60 (17), p.B32-B32
Main Authors: Lardizabal, Joel, Desai, Harit, O'Neill, Brian, Macon, Conrad, Alex, Rodriguez, O'Neill, Carol, Fayaz, Ahmed, Martinez, Claudia, Alfonso, Carlos, Martin, Bilsker, Carillo, Roger, Cohen, Mauricio, Heldman, Alan, Williams, Donald, O'Neill, William
Format: Article
Language:English
Subjects:
Cardiology
Cardiovascular
Heart attacks
Internal Medicine
Mortality
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The Edwards SAPIEN valve has been FDA-approved with its Retroflex delivery system for retrograde transfemoral (TF) treatment of inoperable patients with severe aortic stenosis, and is the only device clinically available for transcatheter aortic valve replacement (TAVR) in the United States (US). Because of insufficient iliofemoral vascular access, many patients are excluded from the TF approach.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2012.08.119